

VASCULITIS FOUNDATION

FINANCIAL STATEMENTS

June 30, 2015 and 2014

VASCULITIS FOUNDATION

TABLE OF CONTENTS

	<u>Page</u>
Independent Auditors' Report	1-2
Financial Statements:	
Statements of Financial Position	3
Statements of Activities	4
Statements of Functional Expenses.....	5
Statements of Cash Flows.....	6
Notes to Financial Statements	7-12



4600 Madison, Suite 120
Kansas City, MO 64112
P 816.931.6111 F 816.931.8499

11111 Nall Ave., Ste 102
Leawood, KS 66211
P 913.663.1137 F 913.451.0283

www.novakbirkspc.com

INDEPENDENT AUDITORS' REPORT

To the Board of Directors
Vasculitis Foundation
Kansas City, Missouri

Report on the Financial Statements

We have audited the accompanying financial statements of Vasculitis Foundation (a nonprofit Organization), which comprise the statement of financial position as of June 30, 2015 and 2014, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

B E P O S I  I V E .

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Vasculitis Foundation as of June 30, 2015 and 2014, and the changes in its net assets, functional expenses, and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Novak Birks P.C.

Novak Birks, PC
August 21, 2015

VASCULITIS FOUNDATION
STATEMENTS OF FINANCIAL POSITION
June 30, 2015 and 2014

	2015	2014
<u>ASSETS</u>		
Cash and cash equivalents	\$ 42,035	\$ 33,201
Funds held by Northland Community Foundation	1,108,768	1,143,434
Grants receivable	39,955	31,256
Prepaid expenses	0	5,460
Furniture and equipment, less accumulated depreciation	670	1,203
Total Assets	\$ 1,191,428	\$ 1,214,554

LIABILITIES AND NET ASSETS

Liabilities:		
Accounts payable	\$ 5,820	\$ 4,510
Accrued liabilities	31,172	29,785
Deferred revenue	0	635
Total Liabilities	36,992	34,930
Net Assets		
Unrestricted	94,118	-
Unrestricted - Board designated - endowment	193,597	155,182
Total Unrestricted Net Assets	287,715	155,182
Temporarily restricted net assets	866,721	1,024,442
Total Net Assets	1,154,436	1,179,624
Total Liabilities and Net Assets	\$ 1,191,428	\$ 1,214,554

The accompanying notes are an integral part of
this financial statement.

B E P O S I  I V E .

VASCULITIS FOUNDATION
STATEMENT OF ACTIVITIES
For The Years Ended June 30, 2015 and 2014

	2015	2014
<u>UNRESTRICTED NET ASSETS</u>		
Revenues and Other Support:		
General donations	\$ 296,925	\$ 284,530
Dues	43,107	47,624
Memorials	29,209	34,882
In-kind contributions	3,980	10,374
Honors	34,824	30,568
Other	2,259	3,457
Symposium revenue	45,860	64,251
Interest and dividends	4,230	4,008
Unrealized gain (loss)	1,146	(7,819)
Realized gain (loss)	650	30,103
	462,190	501,978
Net Assets released from restrictions	703,556	358,614
	1,165,746	860,592
Expenses:		
Patient support, awareness, and research	908,411	713,377
Administrative	64,071	84,465
Fundraising	60,731	23,601
Total Expenses	1,033,213	821,443
Change in Unrestricted Net Assets	132,533	39,149
<u>TEMPORARILY RESTRICTED NET ASSETS</u>		
Revenues		
Restricted donations	532,329	335,666
Interest and dividends	12,109	12,630
Unrealized gain (loss)	(436)	(6,227)
Realized gain (loss)	1,833	45,523
Net asset released from restrictions	(703,556)	(358,614)
Change in Temporarily Restricted Net Assets	(157,721)	28,978
Change in Net Assets	(25,188)	68,127
Net Assets, beginning of year	1,179,624	1,111,497
Net Assets, end of year	\$ 1,154,436	\$ 1,179,624

The accompanying notes are an integral part of
this financial statement.

B E P O S I  I V E .

VASCULITIS FOUNDATION
STATEMENTS OF FUNCTIONAL EXPENSES
For the Years Ended June 30, 2015 and 2014

	2015				2014			
	Patient Support, Awareness, and Research	Administrative	Fundraising	Total	Patient Support, Awareness, and Research	Administrative	Fundraising	Total
	\$	\$	\$	\$	\$	\$	\$	\$
Supporting Services	208,699	30,850	11,008	250,557	174,116	36,138	9,118	219,372
Grants paid	338,004	-	-	338,004	183,792	-	-	183,792
Salaries and Wages	129,368	25,873	-	155,241	78,947	29,814	-	108,761
Newsletter	31,153	-	-	31,153	36,356	-	-	36,356
Symposium and conferences	110,763	-	-	110,763	167,061	-	-	167,061
Member information	43,436	-	-	43,436	37,653	-	-	37,653
Event costs	7,613	-	49,723	57,336	7,687	-	14,483	22,170
Payroll taxes and benefits	19,532	1,758	-	21,290	11,152	5,541	-	16,693
In-kind expenses	1,491	1,491	-	2,982	4,962	4,963	-	9,925
Board expenses	3,966	3,966	-	7,932	7,910	7,910	-	15,820
Medical Conferences	13,386	-	-	13,386	2,844	-	-	2,844
Depreciation	400	133	-	533	297	99	-	396
Memberships	600	-	-	600	600	-	-	600
TOTAL EXPENSES	\$ 908,411	\$ 64,071	\$ 60,731	\$ 1,033,213	\$ 713,377	\$ 84,465	\$ 23,601	\$ 821,443

The accompanying notes are an integral part of these financial statements.

VASCULITIS FOUNDATION
STATEMENT OF CASH FLOWS
For The Years Ended June 30, 2015 and 2014

	2015	2014
Cash Flows From Operating Activities:		
Change in net assets	\$ (25,188)	\$ 68,127
Adjustments to reconcile increase in net assets to net cash flows from operating activities:		
Depreciation	533	396
Realized (gain) loss on investments	(2,483)	(75,626)
Unrealized (gain) loss on Investments	(456)	14,046
(Increase) decrease in:		
Grants receivable	(8,699)	(31,256.00)
Prepaid expenses	5,460	790
Deposits	0	500.00
Increase (decrease) in:		
Accounts payable	1,310	3,299
Accrued liabilities	1,386	7,662
Deferred revenue	(635)	(42,995)
Net Cash Provided by Operating Activities	(28,772)	(55,057)
 Cash Flows From Investing Activities:		
Purchases of furniture and equipment	0	(1,600)
Transfers from Northland Community Foundation	220,000	100,103
Transfers to Northland Community Foundation	(182,394)	(32,025)
Net Cash From (Used In) Investing Activities	37,606	66,478
 Net Change In Cash	8,834	11,421
 Cash, beginning of year	33,201	21,780
 Cash, end of year	\$ 42,035	\$ 33,201

The accompanying notes are an integral part of
this financial statement.

B E P O S I  I V E .

VASCULITIS FOUNDATION
NOTES TO FINANCIAL STATEMENTS
June 30, 2015 and 2014

NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization – Vasculitis Foundation (The Foundation) is the largest patient support group and the only international organization for vasculitis patients and their loved ones. Vasculitis is a rare autoimmune disease that strikes people of all ages. There are at least fifteen known vasculitic diseases. There is no known cause or cure. Early diagnosis is critical to patients. Without effective treatment, the disease is fatal.

Through a newsletter, a website, information packets, medical consultants, symposiums, as well as area contacts and chapters, the Foundation works to raise awareness of vasculitis, educate patients about the disease, and support research into the cause, cure and treatment of the disease.

Donated Materials and Services – Donated materials are reflected as contributions in the accompanying financial statements at their fair values at the date of receipt. The Foundation records donated services to the extent that they create or enhance non-financial assets or that they require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation. The Foundation had \$3,980 and \$10,374 of in-kind contributions for research and travel expenses for the years ended June 30, 2015 and 2014., respectively. Additionally, the Foundation had \$5,614 and \$0 in general in-kind contributions for the year ended June 30, 2015 and 2014., respectively.

Furniture and Equipment – The Foundation capitalizes all significant additions of property and equipment, which are recorded at acquisition cost if purchased, or fair value, if donated. Depreciation is provided on a straight line basis over three years.

Income Taxes – The Foundation qualifies as tax exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code.

The Foundation recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax position meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.

The Foundation is subject to income tax regulations in the U.S. federal jurisdiction and certain state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. With few exceptions, the Foundation is no longer subject to income tax examinations by the applicable tax authorities for the years before 2012. If any were to be incurred, the Foundation's policy is to record penalties and interest assessed by income tax authorities as operating expenses.

Cash Equivalents – For purpose of the statement of cash flows, the Foundation considers highly liquid investments purchased with initial maturities of less than three months to be cash equivalents. Included in cash equivalents at June 30, 2015 and 2014 was \$8,381 and \$3,340, respectively, held in money market funds at an investment company that were not insured by the Federal Deposit Insurance Corporation.

VASCULITIS FOUNDATION
NOTES TO FINANCIAL STATEMENTS
June 30, 2015 and 2014

NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Expense Allocation- The Foundation allocates its expenses on a functional basis among its program, administrative, and fundraising activities. Administrative expenses include those expenses that are not directly identifiable with any other specific function but provide for the overall support and direction of the Foundation.

Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Research Funds – All donations that are designated for research are placed in the Foundation's Research Fund, which supports the Foundation's Research Program. The purpose of the Research Program is to provide one-year seed grants to support pilot studies in researching the etiology; epidemiology; diagnosis; treatment, including approaches that would prevent complications; and development of coping skills for living with the disease.

Awards are provided up to \$50,000 for a one-year study and up to \$100,000 for a two-year study. Smaller awards are also allowed. Suitable applicants are medical researchers in areas such as, but not limited to, rheumatology, immunology, nephrology, otolaryngology, pulmonary and respiratory diseases, and internal medicine.

Applications are reviewed by the Foundation's Research Committee and Scientific Advisory Board. Each investigator is required to submit a six-month progress report, including financial data. A final report is also required and is due within sixty days of the last day of the study and must also include a financial report. Donations designated for research may not be used to support any other program or activity of the Foundation, and are classified as temporarily restricted revenues and net assets.

Subsequent Events – Subsequent events have been evaluated through August 21, 2015, which is the date the financial statements were available to be issued.

NOTE B – FAIR VALUE MEASUREMENTS

FASB ASC 820, *Fair Value Measurements and Disclosures*, provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements).

VASCULITIS FOUNDATION
NOTES TO FINANCIAL STATEMENTS
June 30, 2015 and 2014

NOTE B – FAIR VALUE MEASUREMENTS (Continued)

The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:

- | | |
|---------|---|
| Level 1 | Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability access. |
| Level 2 | Inputs to the valuation methodology include <ul style="list-style-type: none">• quoted prices for similar assets or liabilities in active markets;• quoted prices for identical or similar assets or liabilities in inactive markets;• inputs other than quoted prices that are observable for the asset or liability;• inputs that are derived principally from or corroborated by observable market data by correlation or other means. <p>If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.</p> |
| Level 3 | Inputs to the valuation methodology are unobservable and significant to the fair value measurement. |

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at June 30, 2015 and 2014.

- Funds held by the Northland Community Foundation are valued based on quoted prices for the underlying securities assets or liabilities and are classified within Level 2 of the fair value hierarchy.

The following table sets forth by level, within the fair value hierarchy, the Plan's assets at fair value as of June 30, 2015 and 2014.

VASCULITIS FOUNDATION
NOTES TO FINANCIAL STATEMENTS
June 30, 2015 and 2014

NOTE B – FAIR VALUE MEASUREMENTS (Continued)

	<i>Assets at Fair Value as of June 30, 2015</i>			
	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Funds held by Northland Community Foundation:				
Money market pool	\$ 379,700	\$ -	\$ 379,700	\$ -
Fixed income pool	469,544	-	469,544	-
Equity pool	<u>259,524</u>	<u>-</u>	<u>259,524</u>	<u>-</u>
	<u>\$1,108,768</u>	<u>\$ -</u>	<u>\$ 1,108,768</u>	<u>\$ -</u>

	<i>Assets at Fair Value as of June 30, 2014</i>			
	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Funds held by Northland Community Foundation:				
Money market pool	\$ 379,143	\$ -	\$ 379,143	\$ -
Fixed income pool	491,324	-	491,324	-
Equity pool	<u>272,967</u>	<u>-</u>	<u>272,967</u>	<u>-</u>
	<u>\$1,143,434</u>	<u>\$ -</u>	<u>\$ 1,143,434</u>	<u>\$ -</u>

NOTE C – FURNITURE AND EQUIPMENT

Furniture and equipment consists of:

	<u>2015</u>	<u>2014</u>
Furniture and equipment	\$ 6,380	\$ 6,380
Website costs	<u>49,147</u>	<u>49,147</u>
	55,527	55,527
Accumulated depreciation	<u>(54,857)</u>	<u>(54,324)</u>
	<u>\$ 670</u>	<u>\$ 1,203</u>

Depreciation expense for the years ended June 30, 2015 and 2014 is \$533 and \$396.

NOTE D – Leases

The Foundation leased office space under an operating lease which expired in October 2013. Office rent expense was \$18,769 for the year ended June 30, 2014. As of November 1, 2013, the Foundation closed their main office location in Kansas City, Missouri. As of this date, the Executive Director and all of the Foundation's employees began maintaining offices in their homes.

VASCULITIS FOUNDATION
 NOTES TO FINANCIAL STATEMENTS
 June 30, 2015 and 2014

NOTE E – TEMPORARILY RESTRICTED NET ASSETS

Temporarily restricted net assets consisted of the following at June 30:

	2015	2014
Research	\$ 845,096	\$ 930,097
Patient education and support	21,625	94,345
	\$ 866,721	\$1,024,442

NOTE F – UNRESTRICTED BOARD DESIGNATED ENDOWMENT FUNDS

The Foundation has set aside certain funds that it has board-designated to be treated similarly to an endowment. Such funds are to generate a long-term, total rate of return that will increase the value of the assets. The Foundation's endowment assets, which are held in various investment pools at the Northland Community Foundation, totaled \$193,597 and \$155,182 at June 30, 2015 and 2014, respectively.

The Foundation has established investment policies for its board-designated endowment fund. These policies provide for investing approximately 65% of the funds in the equity pool, approximately 35% in the fixed income pool, and less than 1% of the funds in the money market pool. All expenditures of these funds are approved by the Board of Directors. The following table presents a reconciliation of the beginning and ending balances of these endowment funds:

Balance at June 30, 2013	\$116,033
Additions	14,583
Expenditures and fees	(1,327)
Investment income	3,915
Gain on investments	21,978
Balance at June 30, 2014	\$155,182
Additions	33,743
Expenditures and fees	(1,392)
Investment income	4,014
Gain on investments	2,050
Balance at June 30, 2015	\$193,597

NOTE G – CONCENTRATIONS

The Foundation invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the value of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the accompanying statements of financial position.

VASCULITIS FOUNDATION
NOTES TO FINANCIAL STATEMENTS
June 30, 2015 and 2014

NOTE H – DEFERRED REVENUE

The Foundation typically receives fees and registrations for Symposiums to be held at a future date. These funds are classified as deferred revenues until such time as the events occur. At that time, the fees are reclassified to current year revenues. Deferred revenues totaled \$635 at June 30, 2014. There were no deferred revenues at June 30, 2015.